---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037603"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:56:50.062623+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track

## Summary
- Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.
- Cash, equivalents and marketable securities $198.7M as of June 30, 2025; cash runway into 2028.
- FHD-909 Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; preclinical combo data with pembrolizumab and KRAS inhibitors.
- Selective CBP degrader targeting IND in 2026; selective EP300 and ARID1B degrader updates expected Q4 2025.
- R&D expenses decreased to $21.8M from $23.8M; G&A expenses decreased to $6.9M from $7.3M.

## SEC filing metadata
- accession: 0001628280-25-037603
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/0001628280-25-037603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/fhtx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037603
- JSON: https://secwatch.observer/filing/0001628280-25-037603.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.